Thanks for writing it up! I think what isn´t totally clear on 1st glance is that RPTX did not sell off lunre completely in that Debiopharm deal. That covers only that specific combination if I read the terms correctly.
That leaves the P3-ready lunre/camo still on the books (data has not been stellar of course...) and available for partnering in tandem or in other combinations. Given the very advanced stage and probably comprehensive data package, this could become quite meaningful.
I don’t love the idea of buying more necessarily. But if you already owned, I think a flyer on some of the uncapped upside here is worth more than what is being offered here
Thanks for writing it up! I think what isn´t totally clear on 1st glance is that RPTX did not sell off lunre completely in that Debiopharm deal. That covers only that specific combination if I read the terms correctly.
That leaves the P3-ready lunre/camo still on the books (data has not been stellar of course...) and available for partnering in tandem or in other combinations. Given the very advanced stage and probably comprehensive data package, this could become quite meaningful.
Thank you for the write up. Enjoyed reading. What do you think about the cvr structure and viability?
I don’t love the idea of buying more necessarily. But if you already owned, I think a flyer on some of the uncapped upside here is worth more than what is being offered here
Got it. Thanks for the quick reply!